Healthcare, Pharma & Life Sciences

Equip Launches Transition Track to Cut Eating Disorder Readmissions

San Diego – October 07, 2026 -- Equip, a virtual eating disorder treatment provider, has launched Transition Track, a new care protocol designed to move medically stable patients ages 6 to 24 directly from inpatient hospitalization to home-based recovery without stopping at residential, PHP or IOP facilities.

Protocol targets the highest-risk window after hospital discharge

Transition Track is built on Family-Based Treatment (FBT), combining frequent therapy sessions, daily virtual meal supervision and caregiver coaching during the first weeks post-discharge, then continuing with the same multidisciplinary care team for a full 12 months. The approach aligns with guidance from the American Psychiatric Association, the Society for Adolescent Health and Medicine, and the American Academy of Pediatrics, all of which recommend family-supported outpatient care as the first-line treatment for medically stable patients.

Castle Connolly, rater8 Partner on Patient Review Tech for Top Doctors

New York – October 07, 2026 -- Castle Connolly, which has vetted top U.S. healthcare providers for more than 35 years, has partnered with reputation management firm rater8 to deploy automated patient review tools across its national network of Top Doctors, Top Dentists, and Top Hospitals.

Partnership pairs peer-nominated rankings with automated patient feedback collection

Under the deal, Castle Connolly will offer rater8's Visibility Engine (raVE) platform to hospitals, group practices, doctors, and dentists nationwide. The combined offering merges Castle Connolly's independent, peer-nominated provider recognition with rater8's automated system for capturing post-visit patient sentiment and generating online reviews.

SciBase Recalculates TO 2 Warrant Terms After September Rights Issue

Stockholm – October 07, 2026 -- SciBase Holding AB has recalculated the terms of its series TO 2 warrants following a rights issue of shares resolved by its board on September 3, 2026, cutting the subscription ratio to 0.01 shares per warrant.

Subscription price drops to SEK 37.47 per share under new warrant terms

Each TO 2 warrant now entitles the holder to subscribe for 0.01 new shares at SEK 37.47 per share, down from the original terms set when the instrument was issued alongside SciBase's April 2024 capital raise. The adjustment follows contractual provisions requiring recalculation of warrant terms whenever the company conducts a subsequent rights issue.

SciBase Issues 60,000 Shares to Settle SEK 0.9M Guarantor Fee

Stockholm – October 07, 2026 -- SciBase Holding AB has resolved on a set-off share issue of 60,000 new shares to Bergs Securities AB, settling part of the guarantee compensation owed for underwriting the company's recently completed rights issue.

Board approves compensation shares at SEK 15 apiece

The Board of Directors resolved on the Compensation Issue on October 7, 2026, under authorization granted at the Annual General Meeting on May 19, 2026. The subscription price of SEK 15 per share matches the price set in the underlying rights issue. Payment was made entirely through set-off against SEK 0.9 million of Bergs Securities' claim for guarantee compensation, and all 60,000 shares have been subscribed for and allotted.

OncoBayes Advances OB-001 to Clinic After 400% Brain Exposure Gain

LONDON – – October 07, 2026 -- OncoBayes has completed preclinical work on OB-001, an oral drug candidate designed to overcome antibody-drug conjugate (ADC) resistance and boost brain penetration of tyrosine kinase inhibitors (TKIs), the privately held clinical-stage pharmaceutical company announced.

OB-001 raises osimertinib brain exposure by nearly 400% in mouse studies

In perfused-brain mouse models, pretreatment with OB-001 increased brain exposure of osimertinib by almost 400%, while plasma exposure remained broadly unchanged. The data, presented at AACR 2026, covered four gold-standard kinase inhibitors and showed systemic drug levels were largely unaffected by the efflux-pump inhibition.

LG CNS Unveils Pharma Smart Factory AI Suite at CPHI Milan 2026

Milan – October 07, 2026 -- LG CNS is showcasing a pharma-specific manufacturing automation suite at CPHI Milan 2026, the world's largest pharmaceutical and biotech trade show, as the Korean AI transformation firm expands into drug-manufacturing technology. The company is the only Korean participant in CPHI's newly created "AI & Tech" zone this year, presenting its booth under the theme "Autonomous Factory in Pharma."

CPHI Milan draws 60,000 visitors and 3,000 exhibitors from 160 countries

The Milan event is CPHI's flagship show, held annually across global venues including the United States, Europe, Asia and the Middle East, and is considered the premier gathering for pharma and biotech manufacturing technology.

Roche Delivers Molecular Testing Instruments to Boost Ebola Response in DRC

JOHANNESBURG – October 07, 2026 -- Roche Diagnostics has delivered two molecular testing instruments to the Institut National de Santé Publique (INSP) to expand Ebola testing capacity in the Democratic Republic of Congo, as confirmed cases from the Bundibugyo virus outbreak reached 8,067 with 3,901 deaths as of September 28, 2026.

Case fatality rate hits 48.4% across 60 health zones

UN Health Authority data cited by Roche puts the outbreak's case fatality rate at 48.4% across six provinces, with the World Health Organization classifying the risk level in the DRC as very high and maintaining the event as a public health emergency of international concern.

U.S. News Invests in AI Firm Candid to Modernize Senior Living Feedback

Washington – October 07, 2026 -- U.S. News & World Report has made a strategic investment in Candid, an AI-powered engagement startup, to replace static resident surveys with real-time conversational feedback tools across senior living and post-acute care communities.

Candid's conversational platform achieves roughly 70 percent response rates, far outpacing traditional surveys

Candid uses interactive voice and text conversations to let residents, family members and employees provide feedback in their own words. The platform pairs quantitative metrics with qualitative sentiment analysis to flag recurring themes and emerging operational concerns. Across deployments spanning hundreds of U.S. senior living communities, this conversational format averages an approximate 70 percent response rate.

Astellas to Present 21 Oncology Abstracts at ESMO 2026

Tokyo – October 07, 2026 -- Astellas Pharma Inc. (TSE: 4503) will present 21 abstracts from its oncology portfolio at the European Society for Medical Oncology Congress 2026, running October 23-27 in Madrid, Spain.

Enfortumab vedotin combination shows longest follow-up data yet in urothelial cancer

Presentations on PADCEV (enfortumab vedotin) plus pembrolizumab include the longest follow-up reported to date for patients with locally advanced or metastatic urothelial cancer, alongside subgroup and treatment-setting analyses. Additional data cover trials in progress evaluating bladder preservation strategies in muscle-invasive bladder cancer.

Cell Culture Biosensor Market to Hit $906.56M by 2032, Up 10.3% CAGR

London – October 07, 2026 -- The global cell culture monitoring biosensors market is set to more than double from USD 413.8 million in 2024 to USD 906.56 million by 2032, expanding at a 10.3% compound annual growth rate, according to a new report from Credence Research Inc. Demand is being driven by biologics manufacturers, cell therapy developers and high-throughput research labs shifting away from manual sampling toward continuous, non-invasive monitoring.

Optical biosensors dominate with 39% technology share in 2024

Optical platforms led the market on strength of real-time, label-free cell analysis capabilities. Electrochemical, mechanical and microfluidic biosensors are gaining ground as labs integrate sensing hardware with automated culture platforms to cut manual intervention and flag process deviations earlier.